Étiquette : ptsd

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis, Mallory J. E. Loflin et al., 2019

A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722   ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite

Is cannabis an effective treatment for anxiety disorders ?, Anxiety.org, septembre 2019

Is cannabis an effective treatment for anxiety disorders ? https://www.anxiety.org/is-cannabis-an-effective-treatment-for-anxiety-what-research-shows Lindsey Salerno, M.Ed. from Philadelphia College of Osteopathic Medicine Jesse McCann, B.S. from University of Pennsylvania, School of Medicine Shari Lieblich, B.S. from University of Pennsylvania, School of Medicine Jeremy Tyler, Psy.D. from University of Pennsylvania Is cannabis really an effective treatment for anxiety? Research and evidence shows mixed results so learn the facts here and consult a professional. Facts v. Fiction: What the research says What is cannabis (marijuana)? What are common misconceptions? Yes - cannabis can be an effective anxiety treatment - but the opposite is also true Participate in a clinical trial [...]

Lire la suite

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders, Toby Lea et al., 2020

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0   Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]

Lire la suite

Psychedelics and Psychedelic-Assisted Psychotherapy, Collin M. Reiff et al., 2019

Psychedelics and Psychedelic-Assisted Psychotherapy Collin M. Reiff, M.D., Elon E. Richman, M.D., Charles B. Nemeroff, M.D., Ph.D., Linda L. Carpenter, M.D., Alik S. Widge, M.D., Ph.D., Carolyn I. Rodriguez, M.D., Ph.D., Ned H. Kalin, M.D., William M. McDonald, M.D., and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research AJP in Advance, 2019, 1-20. doi: 10.1176/appi.ajp.2019.19010035   Objective : The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods : Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reportingon“psilocybin,” [...]

Lire la suite

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder, Ingmar Gorman et al., 2020

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder Ingmar Gorman, Alexander B. Belser, Lisa Jerome, Colin Hennigan, Ben Shechet, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, and Allison A. Feduccia Journal of Traumatic Stress, 2020, 1-10. Doi : 10.1002/jts.22479   3,4-Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self-perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data (n = 60) were pooled from three Phase 2 clinical studies employing triple-blind crossover designs. Participants were required to meet DSM-IV-R criteria for [...]

Lire la suite

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline, Allison A. Feduccia et al., 2019

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer and Rick Doblin Frontiers in Psychiatry, 2019, Volume 10, Article 650. doi: 10.3389/fpsyt.2019.00650   Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and lifethreatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4 methylenedioxymethamphetamine [...]

Lire la suite

LSD : microdoses festives, Céline Zünd, Le Temps, mardi 28 janvier 2020

LSD : microdoses festives Céline ZÜND Le Temps, mardi 28 janvier 2020 https://www.letemps.ch/societe/lsd-microdoses-festives?utm_campaign=article_traffic&utm_content=1580242382&utm_medium=social&utm_source=facebook&fbclid=IwAR3v1uDm_lCzk_Bb1XMeRzSxcxr-mHObGhhPeJVK-Fa0y6rczvc3DFJ3H78   La prise de LSD en petites quantités fait toujours plus d'adeptes, dans les milieux festifs, au travail ou en automédication. Or la recherche scientifique ne dispose pas de données fiables sur les véritables effets de cette substance, ni sur ses risques potentiels. Ursina s’est longtemps refusée à la tentation d’accompagner ses nuits festives de substances chimiques. «J’avais peur du mauvais trip», dit la Zurichoise de 40 ans, casquette et bomber satiné. Jusqu’à ce qu’elle entende parler du LSD en microdose. Elle se procure l’hallucinogène une première fois il y [...]

Lire la suite

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, 2019

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367   Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]

Lire la suite

La médecine psychédélique renaît peu à peu, France Inter, L’invité de 6h20, vendredi 14 février 2020, sur le site du CIRC

L’invité de 6h20 – La médecine psychédélique renaît peu à peu Fév15 Revue de presse vendredi 14 février 2020 par Mathilde Munos Stéphanie Chayet, journaliste, auteure de Phantastica, ces substances interdites qui guérissent (Grasset) Stéphanie Chayet : “Il n’y a pas plus de troubles psychiatriques chez les usagers de drogues psychédéliques Après le cannabis thérapeutique, verra-t-on d’autres substances, aujourd’hui considérées comme des drogues, devenir des médicaments ? , nous en parlons avec la journaliste Stéphanie Chayet, auteure de « Phantastica ». Elle est l’invitée du 5/7.   https://www.circ-asso.net/linvite-de-6h20-la-medecine-psychedelique-renait-peu-a-peu/ Lecteur audio 00:00 00:00 Source : franceinter.fr Catégorie Revue de presse 15 février 2020

Lire la suite